HONG KONG – Founded only last year, Boston-Shanghai clinical-stage biotech startup Anji Pharmaceuticals Inc. is using its team's ties to big pharma to bring in valuable assets to be developed for indications suffered by Chinese patients, especially metabolic diseases. Most recently, it in-licensed Novartis AG's pradigastat, an inhibitor of acyl coA: diacylglycerol acyl transferase, or DGAT1, which has progressed to phase III testing in familial chylomicronemia syndrome (FCS).